NDLI: Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma

Content Provider	Springer Nature : BioMed Central
Author	Cheng, Lijun Pandya, Pankita H. Liu, Enze Chandra, Pooja Wang, Limei Murray, Mary E. Carter, Jacquelyn Ferguson, Michael Saadatzadeh, Mohammad Reza Bijangi-Visheshsaraei, Khadijeh Marshall, Mark Li, Lang Pollok, Karen E. Renbarger, Jamie L.
Abstract	Background While most pediatric sarcomas respond to front-line therapy, some bone sarcomas do not show radiographic response like soft-tissue sarcomas (rhabdomyosarccomas) but do show 90% necrosis. Though, new therapies are urgently needed to improve survival and quality of life in pediatric patients with sarcomas. Complex chromosomal aberrations such as amplifications and deletions of DNA sequences are frequently observed in pediatric sarcomas. Evaluation of copy number variations (CNVs) associated with pediatric sarcoma patients at the time of diagnosis or following therapy offers an opportunity to assess dysregulated molecular targets and signaling pathways that may drive sarcoma development, progression, or relapse. The objective of this study was to utilize publicly available data sets to identify potential predictive biomarkers of chemotherapeutic response in pediatric Osteosarcoma (OS), Rhabdomyosarcoma (RMS) and Ewing’s Sarcoma Family of Tumors (ESFTs) based on CNVs following chemotherapy (OS n = 117, RMS n = 64, ESFTs n = 25 tumor biopsies). Methods There were 206 CNV profiles derived from pediatric sarcoma biopsies collected from the public databases TARGET and NCBI-Gene Expression Omnibus (GEO). Through our comparative genomic analyses of OS, RMS, and ESFTs and 22,255 healthy individuals called from the Database of Genomic Variants (DGV), we identified CNVs (amplifications and deletions) pattern of genomic instability in these pediatric sarcomas. By integrating CNVs of Cancer Cell Line Encyclopedia (CCLE) identified in the pool of genes with drug-response data from sarcoma cell lines (n = 27) from Cancer Therapeutics Response Portal (CTRP) Version 2, potential predictive biomarkers of therapeutic response were identified. Results Genes associated with survival and/recurrence of these sarcomas with statistical significance were found on long arm of chromosome 8 and smaller aberrations were also identified at chromosomes 1q, 12q and x in OS, RMS, and ESFTs. A pool of 63 genes that harbored amplifications and/or deletions were frequently associated with recurrence across OS, RMS, and ESFTs. Correlation analysis of CNVs from CCLE with drug-response data of CTRP in 27 sarcoma cell lines, 33 CNVs out of 63 genes correlated with either sensitivity or resistance to 17 chemotherapies from which actionable CNV signatures such as IGF1R, MYC, MAPK1, ATF1, and MDM2 were identified. These CNV signatures could potentially be used to delineate patient populations that will respond versus those that will not respond to a particular chemotherapy. Conclusions The large-scale analyses of CNV-drug screening provides a platform to evaluate genetic alterations across aggressive pediatric sarcomas. Additionally, this study provides novel insights into the potential utilization of CNVs as not only prognostic but also as predictive biomarkers of therapeutic response. Information obtained in this study may help guide and prioritize patient-specific therapeutic options in pediatric bone and soft-tissue sarcomas.
Related Links	https://bmcmedgenomics.biomedcentral.com/counter/pdf/10.1186/s12920-018-0456-5.pdf
Ending Page	106
Page Count	18
Starting Page	89
File Format	HTM / HTML
ISSN	17558794
DOI	10.1186/s12920-018-0456-5
Journal	BMC Medical Genomics
Issue Number	1
Volume Number	12
Language	English
Publisher	BioMed Central
Publisher Date	2019-01-31
Access Restriction	Open
Subject Keyword	Human Genetics Microarrays Gene Expression Copy number variation Pediatric sarcomas Precision medicine Prognostic biomarkers Comparative genomic hybridization-array
Content Type	Text
Resource Type	Article
Subject	Genetics (clinical) Genetics
Journal Impact Factor	2.1/2023
5-Year Journal Impact Factor	2.5/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Hybridization and amplification rate correction for affymetrix SNP arrays

Distinctions in gastric cancer gene expression signatures derived from laser capture microdissection versushistologic macrodissection

DNA Copy Number Analysis in Gastrointestinal Stromal Tumors Using Gene Expression Microarrays

Identification of genomic copy number variations associated with specific clinical features of head and neck cancer

Progression risk assessments of individual non-invasive gastric neoplasms by genomic copy-number profile and mucin phenotype

DNA Copy Number Analysis in Gastrointestinal Stromal Tumors Using Gene Expression Microarrays

Correlating genomic copy number alterations with clinicopathologic findings in 75 cases of hepatocellular carcinoma

Identification of genes with a correlation between copy number and expression in gastric cancer

Comparative genomic hybridization to detect variation in the copy number of large DNA segments.

Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma

Similar Documents

Hybridization and amplification rate correction for affymetrix SNP arrays

Distinctions in gastric cancer gene expression signatures derived from laser capture microdissection versushistologic macrodissection

DNA Copy Number Analysis in Gastrointestinal Stromal Tumors Using Gene Expression Microarrays

Identification of genomic copy number variations associated with specific clinical features of head and neck cancer

Progression risk assessments of individual non-invasive gastric neoplasms by genomic copy-number profile and mucin phenotype

DNA Copy Number Analysis in Gastrointestinal Stromal Tumors Using Gene Expression Microarrays

Correlating genomic copy number alterations with clinicopathologic findings in 75 cases of hepatocellular carcinoma

Identification of genes with a correlation between copy number and expression in gastric cancer

Comparative genomic hybridization to detect variation in the copy number of large DNA segments.

Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma